CA2741333C - Vaccine against african horse sickness virus - Google Patents

Vaccine against african horse sickness virus Download PDF

Info

Publication number
CA2741333C
CA2741333C CA2741333A CA2741333A CA2741333C CA 2741333 C CA2741333 C CA 2741333C CA 2741333 A CA2741333 A CA 2741333A CA 2741333 A CA2741333 A CA 2741333A CA 2741333 C CA2741333 C CA 2741333C
Authority
CA
Canada
Prior art keywords
ahsv
seq
virus
vector
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2741333A
Other languages
English (en)
French (fr)
Other versions
CA2741333A1 (en
Inventor
Jules Maarten Minke
Jean-Christophe Audonnet
Alan John Guthrie
Nigel James Maclachlan
Jiansheng Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Boehringer Ingelheim Animal Health USA Inc
University of Pretoria
Original Assignee
University of California San Diego UCSD
Merial Inc
University of Pretoria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41818403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2741333(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California San Diego UCSD, Merial Inc, University of Pretoria filed Critical University of California San Diego UCSD
Publication of CA2741333A1 publication Critical patent/CA2741333A1/en
Application granted granted Critical
Publication of CA2741333C publication Critical patent/CA2741333C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2741333A 2008-10-24 2009-10-22 Vaccine against african horse sickness virus Active CA2741333C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10807508P 2008-10-24 2008-10-24
US61/108,075 2008-10-24
US16351709P 2009-03-26 2009-03-26
US61/163,517 2009-03-26
PCT/US2009/061669 WO2010048394A2 (en) 2008-10-24 2009-10-22 Vaccine against african horse sickness virus

Publications (2)

Publication Number Publication Date
CA2741333A1 CA2741333A1 (en) 2010-04-29
CA2741333C true CA2741333C (en) 2018-02-13

Family

ID=41818403

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2741333A Active CA2741333C (en) 2008-10-24 2009-10-22 Vaccine against african horse sickness virus

Country Status (19)

Country Link
US (3) US8168200B2 (https=)
EP (1) EP2358742B1 (https=)
JP (1) JP2012506699A (https=)
KR (1) KR101719005B1 (https=)
CN (1) CN102245627A (https=)
AP (1) AP3334A (https=)
AR (1) AR074055A1 (https=)
AU (1) AU2009308331C1 (https=)
BR (2) BRPI0920622B1 (https=)
CA (1) CA2741333C (https=)
CL (1) CL2011000922A1 (https=)
EA (1) EA024111B1 (https=)
ES (1) ES2681693T3 (https=)
MX (1) MX2011004219A (https=)
NZ (2) NZ598605A (https=)
PL (1) PL2358742T3 (https=)
PT (1) PT2358742T (https=)
WO (1) WO2010048394A2 (https=)
ZA (1) ZA201103031B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598605A (en) * 2008-10-24 2014-04-30 Merial Ltd Vaccine against african horse sickness virus
EP3466443B1 (en) 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
AP2016009610A0 (en) * 2014-11-04 2016-12-31 Deltamune Pty Ltd Live attenuated african horsesickness virus
US11233998B2 (en) 2015-05-29 2022-01-25 Qualcomm Incorporated Coding data using an enhanced context-adaptive binary arithmetic coding (CABAC) design
CN111867637B (zh) * 2018-03-19 2024-05-03 勃林格殷格翰动物保健有限公司 新ehv插入位点ul43
US12581092B2 (en) 2022-03-03 2026-03-17 Qualcomm Incorporated Temporal initialization points for context-based arithmetic coding
CN116041447A (zh) * 2022-12-29 2023-05-02 北京亿森宝生物科技有限公司 一种检测非洲马瘟病毒的试剂盒及其应用
CN116656731B (zh) * 2023-05-25 2024-04-12 军事科学院军事医学研究院军事兽医研究所 一种表达非洲猪瘟病毒多种蛋白的重组金丝雀痘病毒及其构建方法
EP4520797A1 (en) 2023-07-07 2025-03-12 Chukyo Yushi Co., Ltd. Dispersion
CN117737310B (zh) * 2024-01-26 2024-07-16 中国农业科学院北京畜牧兽医研究所 非洲马瘟和西尼罗病毒的双重实时荧光mira检测引物探针组、试剂盒及方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
ZA976424B (en) * 1996-07-05 1999-01-22 Agricultural Research Council Nucleic acid sequences coding for african horsesickness virus outer capsid components
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) * 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
US7862821B2 (en) * 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
NZ598605A (en) * 2008-10-24 2014-04-30 Merial Ltd Vaccine against african horse sickness virus

Also Published As

Publication number Publication date
AR074055A1 (es) 2010-12-22
AU2009308331C1 (en) 2015-07-09
JP2012506699A (ja) 2012-03-22
AU2009308331B2 (en) 2014-08-21
ES2681693T3 (es) 2018-09-14
EA024111B1 (ru) 2016-08-31
EP2358742A2 (en) 2011-08-24
BR122019001455B1 (pt) 2021-01-19
CL2011000922A1 (es) 2011-09-16
WO2010048394A3 (en) 2010-08-19
US8168200B2 (en) 2012-05-01
US20140120133A1 (en) 2014-05-01
ZA201103031B (en) 2014-03-26
CA2741333A1 (en) 2010-04-29
KR20110092281A (ko) 2011-08-17
BRPI0920622A8 (pt) 2019-02-05
WO2010048394A2 (en) 2010-04-29
MX2011004219A (es) 2011-09-22
KR101719005B1 (ko) 2017-03-22
EA201100674A1 (ru) 2011-12-30
CN102245627A (zh) 2011-11-16
AU2009308331A1 (en) 2010-04-29
BRPI0920622B1 (pt) 2019-11-12
US20120114691A1 (en) 2012-05-10
BRPI0920622A2 (pt) 2016-10-04
AP3334A (en) 2015-07-31
PL2358742T3 (pl) 2018-08-31
NZ598605A (en) 2014-04-30
AP2011005954A0 (en) 2011-10-31
EP2358742B1 (en) 2018-02-28
PT2358742T (pt) 2018-06-04
NZ592388A (en) 2012-03-30
US20100119546A1 (en) 2010-05-13

Similar Documents

Publication Publication Date Title
CA2741333C (en) Vaccine against african horse sickness virus
TWI399213B (zh) 抗藍舌病病毒之重組疫苗
US10537632B2 (en) Canine parvovirus (CPV) virus-like particle (VLP) vaccines and uses thereof
CA2605629C (en) Nipah virus vaccines
CA2876196C (en) Reassortant btv vaccines
AU2014218358B2 (en) Vaccine against african horse sickness virus
KR102934156B1 (ko) Fcv 재조합 백신 및 그의 용도
US20050031641A1 (en) Recombinant vaccine against West Nile Virus
HK1157360B (en) Vaccine against african horse sickness virus
HK1157360A (en) Vaccine against african horse sickness virus
HK1219412A1 (zh) 对抗尼罗热病毒的疫苗

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141003

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251013

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251013